The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future

TY - JOUR

T1 - The Microbiome and Hematopoietic Cell Transplantation

T2 - Past, Present, and Future

AU - Blood and Marrow Transplant Clinical Trials Network

AU - Andermann, Tessa M.

AU - Peled, Jonathan U.

AU - Ho, Christine

AU - Reddy, Pavan

AU - Riches, Marcie

AU - Storb, Rainer

AU - Teshima, Takanori

AU - van den Brink, Marcel R.M.

AU - Alousi, Amin

AU - Balderman, Sophia

AU - Chiusolo, Patrizia

AU - Clark, William B.

AU - Holler, Ernst

AU - Howard, Alan

AU - Kean, Leslie S.

AU - Koh, Andrew Y.

AU - McCarthy, Philip L.

AU - McCarty, John M.

AU - Mohty, Mohamad

AU - Nakamura, Ryotaro

AU - Rezvani, Katy

AU - Segal, Brahm H.

AU - Shaw, Bronwen E.

AU - Shpall, Elizabeth J.

AU - Sung, Anthony D.

AU - Weber, Daniela

AU - Whangbo, Jennifer

AU - Wingard, John R.

AU - Wood, William A.

AU - Perales, Miguel Angel

AU - Jenq, Robert R.

AU - Bhatt, Ami S.

N1 - Funding Information: Funding: TMA is supported by the American Society of Blood and Marrow Transplantation New Investigator Award and by the NIH/NCATS Clinical and Translational Science Award KL2 TR000083 and UL1 TR001085. ASB is supported by the Damon Runyon Cancer Research Foundation. RRJ is supported by NIH/NHLBI RO1 HL124112 and CPRIT RR160089. JUP, MAP, and MvdB are supported in part by an NIH P01 CA23766 and NIH/NCI P30 CA 008748. The Blood and Marrow Transplant Clinical Trials Network is supported in part by grants #U10HL069294 and #U24HL138660 from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: Conflict of interest statement: J.U.P receives licensing fees and research support from Seres Therapeutics. M.v.d.B receives research support from Seres Therapeutics and has served as a consultant for Jazz Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Flagship Ventures, Boehringer Ingelheim, Merck, and Evolo. R.R.J is on the advisory committee of and holds patents with or receives royalties from Seres Therapeutics; he has consulted for Ziopharm Oncology. L.S.K consults with and receives funding from Bristol Myers Squibbs and Kymab, Ltd; she receives research funding from Regeneron Pharmaceuticals. M.M.M has received honoraria and research support from MaaT Pharma. Funding Information: Funding: TMA is supported by the American Society of Blood and Marrow Transplantation New Investigator Award and by the NIH/NCATS Clinical and Translational Science Award KL2 TR000083 and UL1 TR001085 . ASB is supported by the Damon Runyon Cancer Research Foundation . RRJ is supported by NIH/NHLBI RO1 HL124112 and CPRIT RR160089 . JUP, MAP, and MvdB are supported in part by an NIH P01 CA23766 and NIH/NCI P30 CA 008748 . The Blood and Marrow Transplant Clinical Trials Network is supported in part by grants #U10HL069294 and #U24HL138660 from the National Heart, Lung, and Blood Institute and the National Cancer Institute . The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

PY - 2018/7

Y1 - 2018/7

KW - Fecal microbiota transplant

KW - Hematopoietic stem cell transplantation

KW - Metagenomics

KW - Microbiome

KW - Microbiota

KW - Prebiotic

UR - http://www.scopus.com/inward/record.url?scp=85049143550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049143550&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.02.009

DO - 10.1016/j.bbmt.2018.02.009

M3 - Comment/debate

C2 - 29471034

AN - SCOPUS:85049143550

SN - 1083-8791

VL - 24

SP - 1322

EP - 1340

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -